After months of back and forth between companies and their management teams, on Wednesday (January 24) Aurora Cannabis (TSX:ACB; OTCQB:ACBFF) managed to secure the acquisition of fellow Licensed Producer (LP) CanniMed Therapeutics (TSX:CMED) in a deal worth approximately $1.1 billion.
Both CanniMed’s board of directors and the special committee formed to investigate the Aurora takeover bid and agreed to support the new offer.
Shareholders for CanniMed will be presented with the option to pick between receiving 3.40 Aurora shares or a cash and shares combination. However, Aurora said there is a maximum $140 million cash dedicated to this resolution.
Brent Zettl, president and CEO of CanniMed went to great ordeals to explain why this acquisition attempt from Aurora wasn’t worth it to his shareholders. In the joint statement, he said the transaction confirmed his company had become a global leader in the medical cannabis market.
The dispute between the two TSX listed LPs had become so tense that CanniMed even raised a $725 million lawsuit against Aurora, claiming “wrongdoing” related to CanniMed’s takeover bid.
CanniMed argued for breaches of confidentiality, intentional interference with economic relations, conversion, and breach of contract among other allegations. In their joint statement, there was no mention or update on the development of the lawsuit.
As the Canadian market prepares for an increase in demand for cannabis as recreational legalization nears, Aurora has been on a path of acquisition over the past few months, seeking to increase their production numbers. With this blockbuster purchase, Aurora is looking to increase its scope when it comes to meeting demand both in and outside of Canada.

Shares of Newstrike decline after being left out of acquisition deal

With the completion of Aurora’s takeover bid, the deal in place for Newstrike Resources (TSXV:HIP) to be acquired by CanniMed has effectively been canceled. This case proved to be a contentious fight for Aurora, as they made their hostility against this deal clear.
The acquisition of Newstrike was deemed a “poison pill” tactic meant to get rid of Aurora’s takeover attempt for CanniMed.
Newstrike issued a statement announcing the deal, one that their shareholders voted in favor of, which then fell through with CanniMed. According to the release, Newstrike is set to receive a $14.1 million package due to the termination of the planned transaction.
Jay Wilgar, CEO of Newstrike, said the company will use the money to increase the efforts for their Niagara Facility greenhouse to begin producing ahead of schedule and to speed up the roll-out of their lifestyle brand Up Cannabis.
The fallout of this deal particularly affects Newstrike after its shareholders showed a vote of confidence by overwhelmingly approving the CanniMed takeover attempt, as part of a special meeting last week.
Earlier in this week reports indicated Aurora was potentially considering bringing Newstrike along in what would have been one of the largest transactions ever in the cannabis industry. On Tuesday (January 23), shares of or Newstrike rose thanks to the speculation, reaching a week-high price of $2.62.
At market closure on Wednesday, Newstrike faced a 19.23 percent decline to its stock while CanniMed soared, reaching a new year high share $43.18 price per share during trading hours and closing with an 85.81 percent increase over a year-to-date period. Aurora, on the other hand, closed the day with a 5.48 percent decline to its share price.


Investor Takeaway

Despite today’s decline for Newstrike, Aaron Salz a cannabis advisor with the independent group Stoic Advisory, tweeted on Wednesday the TSXV listed company was actually the biggest winner from this entire case.

It will be interesting for investors to follow through the full impact this failed deal will have on Newstrike’s share price moving forward.
Editor’s note: This story was updated to reflect the changes in share price for each company at market closure.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less